Immunome, Inc. (IMNM) Earnings Call Transcripts
Immunome, Inc.'s Latest Earnings Call - June 9, 2026
Immunome, Inc. reported its earnings for Q2 2026, highlighting significant developments in its oncology pipeline. The company is preparing to launch its gamma-secretase inhibitor, Veragasistat, with an NDA submitted and awaiting FDA review. Revenue and earnings figures were not disclosed in the transcript, and no changes to financial guidance were mentioned. Key updates included promising Phase III data for Veragasistat in desmoid tumors, showcasing a 56% objective response rate and significant pain reduction. The company is also advancing its ADC platform, with data for IM 1021 expected later this year.
Reported metrics
| Metric | Value |
|---|---|
| Objective Response Rate for Veragasistat | 56% (positive) |
| Median Best Tumor Volume Reduction | 83% (positive) |
| Ovarian Toxicity Rate | 56% (positive) |
| Cash Runway | Into 2028 (neutral) |
Guidance from management
Management did not provide specific financial guidance but emphasized the readiness for Veragasistat's launch and the advancement of its ADC platform.
What management said
Well, I think that your question touches on the key point, right? It's a superior profile. We've had some initial conversations with payers. I think it's our it's a little premature to say, "Oh, here's where your pricing is going to land. But payers are aware that superior drugs frequently get priced out of premium. And we think that, that may be an option, but we haven't completed that work yet. And it's hard to kno...
Yes, that's work that we're still doing. We think that we have a really fantastic drug, and we think that there's unmet need. We're launching a couple of years after OXZIVIO with a substantially better profile.
What analysts pressed on
Analysts expressed interest in the pricing strategy for Veragasistat and its competitive positioning against emerging therapies. There were also questions about the differentiation of Immunome's ADC platform and its potential market impact.
Main topics on the call
- Veragasistat Launch Preparation — Immunome is preparing to launch Veragasistat, with the NDA submitted and awaiting FDA review. The company is building a commercial team and engaging with key opinion leaders to support the launch.
- Phase III Data for Veragasistat — The Phase III study showed a 56% objective response rate and an 83% median best tumor volume reduction. The drug also demonstrated significant pain reduction, achieving a clinically meaningful reduction at four weeks.
- ADC Platform Development — Immunome plans to release data for its ROR1-targeted ADC, IM 1021, later this year. The company is developing three additional ADCs targeting undisclosed solid tumor targets.
- Commercialization and Pricing Strategy — Immunome is building a commercial team and has initiated payer discussions for Veragasistat. The company is considering premium pricing due to the drug's superior profile.
Read the full Immunome, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Immunome, Inc.
Immunome, Inc. (IMNM) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 1 call on record spanning June 9, 2026 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 1 Immunome, Inc. earnings call transcript on record, spanning June 9, 2026 to June 9, 2026. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- IMNM
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 1
- First call
- June 9, 2026
- Most recent
- June 9, 2026
| Quarter | Date | |
|---|---|---|
| Company Conference Presentations | Jun 9, 2026 | Read transcript → |